Updated Medicare Policies on Botulinum Toxin Usage

Five Medicare administrative contractors—CGS, NGS, Noridian, Palmetto, and WPS—have introduced new policies on botulinum toxin usage, effective February 22. These guidelines include updated initial and continuous dosage regulations, coverage limitations, and documentation requirements, such as clinical scales, to validate the medical necessity of treatments for conditions like blepharospasm, migraines, and strabismus.

If treatments exceed the recommended dosage limits for targeted muscles, they are deemed not medically necessary and face denial. Physicians must issue an advanced beneficiary notice (ABN) for any service not considered reasonable by Medicare. If patients seek coverage under these circumstances, the associated claim should be submitted to Medicare Part B, incorporating a -GA modifier to the CPT and/or HCPCS codes. Additional details on the ABN are available on the American Academy of Ophthalmology’s website.

Furthermore, in cases where Medicare Part B mistakenly covers a non-essential service, physicians are required to process a voluntary refund. The policies explicitly exclude botulinum toxin procedures performed for cosmetic reasons from Medicare coverage. Any use for cosmetic purposes results in the procedure being entirely non-covered. For more information and a comprehensive analysis of these new Medicare policies, professionals can visit aao.org/lcds.